A Phase 1/2 interventional study of Gamma-PN3 and Pneumovax-23 in Pneumococcal Infections, sponsored by GPN Vaccines. Completed at 1 site in Australia. Open to participants aged 18 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-18.
Sponsored by GPN Vaccines · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Pneumococcal Infections with a site in Australia — 3 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal Infections · Australia.
Among the 16 studies in Pneumococcal Infections with a site in Australia, this one is the 14th largest by enrollment, is one of 3 that started in 2023, is the only one in phase 1/2, and was the 13th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →3 of the 16 studies in Pneumococcal Infections with a site in Australia are open now. Recruiting first, the newest first:
Pfizer · Sites in Australia, United States, Argentina and 8 more countries
Ages 42 days–98 days · Healthy volunteers
GPN Vaccines · Sites in Australia
Ages 18–69 · Healthy volunteers
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Sites in Australia
Ages 60+ · Healthy volunteers
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 69 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 1 · Phase 3 12
First in 2006; this study’s year is marked. 3 started in 2023.
This study's enrollment of 60 is below the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 851 across the 16 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 16 have an industry lead sponsor. The 6 most frequent:
GPN Vaccines is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
GPN Vaccines has 3 studies filed under Pneumococcal Infections — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Pneumococcal Infections with a site in Australia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A 6 and 12 month safety and immunogenicity study of participants in study GPNV-001, a novel whole-cell pneumococcal vaccine.
A 6 and 12 month safety and immunogenicity study of participants in study GPNV-001, a novel whole-cell pneumococcal vaccine. Up to 20 participants per cohort will be invited.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In GPNV-001 participants will have received 2 doses of 50 mcg Gamma-PN3 at intervals of 4 weeks
Biological: Gamma-PN3
In GPNV-001 participants will have received 2 doses of 250 mcg Gamma-PN3 at intervals of 4 weeks
Biological: Gamma-PN3
In GPNV-001 participants will have received 2 doses of 1000 mcg Gamma-PN3 at intervals of 4 weeks
Biological: Gamma-PN3
In GPNV-001 participants will have received one 0.5ml dose of Pneumovax-23 followed by saline placebo 4 weeks later
Biological: Pneumovax-23
In GPNV-001 participants will have received one 0.5ml dose of Prevenar-13 followed by saline placebo 4 weeks later
Biological: Prevenar-13
In GPNV-001 participants will have received two doses of 0.5 ml saline placebo at intervals of 4 weeks.
Biological: Placebo
Experimental whole-cell pneumococcal vaccine
Drug page: 23-valent pneumococcal capsular polysaccharide vaccineStudies of 23-valent pneumococcal capsular polysaccharide vaccine23-valent pneumococcal capsular polysaccharide vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Licensed pneumococcal vaccine
Licensed pneumococcal vaccine
Saline placebo
Serum IgG titre to Gamma-PN3
Serum IgG titre to the vaccine
Time frame: 6 months and 12 months
Serious adverse events
Serious adverse events occurring after day 57 of study GPNV-001
Time frame: 6 months and 12 months
Opsonophagocytic antibodies to pneumococcal strains
Serum OPA titres to up to 24 pneumococcal serotypes
Time frame: 6 months and 12 months
Plan to share: No — No plan as yet
No publications or documents are linked to this record.
Ran from Jul 2023 to primary completion in Aug 2024, 13 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GPN Vaccines